EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Advances in PET Imaging of α7 Nicotinic Receptors: From Radioligand Development to CNS Applications

Janus H Magnussen iD

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70025 ↗

At a glance

Übersichtsarbeit in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Janus H Magnussen. Institution: Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark. Major MEDLINE topics: alpha7 Nicotinic Acetylcholine Receptor, Positron-Emission Tomography, Radiopharmaceuticals, Central Nervous System Diseases. Cited 5 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Positron emission tomography (PET) has significantly advanced our understanding of the brain by enabling non‐invasive imaging and quantification of molecular processes, including receptor binding. In this review, we explore the development and application of PET radioligands targeting the α7 nicotinic acetylcholine receptor (α7 nAChR), a receptor implicated in various central nervous system (CNS) diseases, such as Alzheimer's disease, schizophrenia and cognitive disorders. Despite challenges associated with the low density of α7 nAChRs and difficulties in achieving adequate brain penetration, several promising radioligands have been developed, including 11 C‐( R )‐MeQAA, 11 C‐NS14492 and 18 F‐ASEM. These radioligands facilitate the evaluation of the ‘three pillars of survival’ in drug development: tissue accessibility, target engagement and downstream pharmacology. PET imaging offers critical insights into drug distribution across the blood–brain barrier, receptor occupancy and the pharmacodynamic effects of α7 nAChR–targeted therapies. By reviewing current radioligands and their applications, we highlight the potential of PET imaging to deepen our understanding of α7 nAChR–mediated signalling pathways and its implications for CNS drug discovery. Future innovations in radioligand development, including more selective and brain‐penetrant compounds, will be key to fully realizing the potential of PET imaging in α7 nAChR–targeted research and treatment.

Subjects

MeSH terms (MEDLINE)

alpha7 Nicotinic Acetylcholine ReceptorPositron-Emission TomographyRadiopharmaceuticalsCentral Nervous System DiseasesHumansAnimalsLigandsBlood-Brain BarrierBrainDrug Development

Author keywords

CNS diseasesPET imagingalpha 7 nicotinic receptorneuroimagingradioligands

Substances

alpha7 Nicotinic Acetylcholine ReceptorRadiopharmaceuticalsLigands

Authors and institutions

  • Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark.

ORCID profiles: Janus H Magnussen

Cite

APA

Magnussen, J. H. (2025). Advances in PET Imaging of α7 Nicotinic Receptors: From Radioligand Development to CNS Applications. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70025

Vancouver

Magnussen JH. Advances in PET Imaging of α7 Nicotinic Receptors: From Radioligand Development to CNS Applications. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70025

BibTeX
@article{Magnussen2025,
  author = {Magnussen, Janus H},
  title = {Advances in PET Imaging of α7 Nicotinic Receptors: From Radioligand Development to CNS Applications},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70025}
}
Start for free →